GlaxoSmithKline: Hepatitis C trials
The registry lists 21 Hepatitis C studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 9Phase 2 5Phase 3 6No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Dose Ranging of GSK2336805 in Combination TherapyCompletedNCT01648140Phase 2Results posted
- Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390CompletedNCT00996216Phase 3Results posted
- Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive ProceduresTerminatedNCT00678587Phase 3Results posted
- Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver DiseaseCompletedNCT00529568Phase 3Results posted
- Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver DiseaseCompletedNCT00516321Phase 3Results posted
- Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.CompletedNCT02014571Phase 1
- A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy SubjectsCompletedNCT01879462Phase 1
- Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control SubjectsCompletedNCT01827657Phase 1
- WEUSKOP5410: Observational Study in ENABLE Clinical TrialsCompletedNCT01458080
- Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy AdultsCompletedNCT01458054Phase 1
- Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805CompletedNCT01424540Phase 1
- A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C SubjectsTerminatedNCT01332552Phase 1
- A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.CompletedNCT01277692Phase 1
- Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.CompletedNCT00833378Phase 1
- A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3CompletedNCT00656006Phase 2
- Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected AdultsTerminatedNCT00439959Phase 1
- Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3CompletedNCT00411385Phase 3
- Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive PatientsCompletedNCT00402428Phase 3
- A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1CompletedNCT00115908Phase 2
- SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis CCompletedNCT00110799Phase 2
- A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis CCompletedNCT00097435Phase 2